Gritstone Oncology
Developing next-generation personalized cancer therapeutics.
loading funding rounds…
GV(exited)
Alexandria Venture Investments(exited)
Versant Ventures(exited)
The Column Group(exited)
Clarus Ventures(exited)
Frazier Healthcare Partners(exited)
Lilly Asia Ventures(exited)
Casdin Capital(exited)
Redmile Group(exited)
Trinitas Partners(exited)
Aberdare Ventures(exited)
Bay City Capital(exited)
Gilead Sciences(exited)
Invus(exited)
Hercules Capital(exited)
BVF Partners(exited)
EcoR1 Capital(exited)
Avidity Partners(exited)
Frazier Life Sciences(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (87 %) | 268 % | (8 %) | 1057 % | (80 %) | (86 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (429 %) | (5191 %) | (2135 %) | (2462 %) | (147 %) | (1278 %) | (9531 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (446 %) | (5457 %) | (2163 %) | (2609 %) | (161 %) | (1291 %) | (10405 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 385 % | 4631 % | 1899 % | 2196 % | 209 % | 1202 % | 9555 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.